New study aims to close transplant gap for AML patients facing racial and economic barriers

NCT ID NCT06370000

Recruiting now Disease control Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking oral azacitidine pills for up to six months can help prevent leukemia from returning in patients who are eligible for a stem cell transplant but cannot get one due to racial or socioeconomic disparities. The trial enrolls 12 adults with acute myeloid leukemia in remission. The main goal is to see if patients can complete at least four cycles of this maintenance therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Oral azacitidine
What this could lead to: If successful, this could offer a practical maintenance option to reduce relapse risk for AML patients who face barriers to transplant.
What could go wrong: This is a very small feasibility study with only 12 participants, so results may not apply broadly. The drug may not prevent relapse or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Virginia Commonwealth University
RECRUITING

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.